Head Of Commercial- Europe

Hiring By - Biostaffic

 BioPharma

Norvenich, Nordrhein-Westfalen - Germany

Job Highlights

Not Disclosed

Posted 4 months ago
Job details

About Burning Rock Dx.

Burning Rock Dx LCC (NASDAQ: BNR), whose mission is to guard life with science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology.

Our business consists of i) NGS-based therapy selection testing for late-stage cancer patients, with the leading market share in China, ii) Global pharmaceutical services on biomarker detection and companion diagnostics developing, and iii) NGS-based cancer early detection, which has entered into commercialization stage.


Day to day responsibilities:

  • Conduct marketing strategy analysis of IVD products, and update market trends & dynamics in Europe;
  • In-depth analysis of IVD related policy in Europe;
  • Deeply understanding of sales model of IVD products in Europe;
  • Develop strategy & action plans for IVD product distribution in Europe;
  • Collaborate with internal & external partners to assist IVD products distribution;
  • Uses global thinking to clearly articulate IVD products’ market positioning and competitiveness across the globe;
  • Communicate and coordinate with different function to get internal alignment and well allocate resources for active projects in strategy plan;

Qualifications:

  • Above Bachelor’s degree of Life Science related majors;
  • IVD products knowledge will be preferred;
  • Strategic-thinking & Global-perspective;

Benefits Offered?

  • No

Bonus Offered?

  • No

Travel Required?

  • No

Location:

  • Norvenich, Nordrhein-Westfalen - Germany

Global Experience Needed?

  • No

Specialized Experience Needed?

  • No

Apply before:

  • Apr 12, 2024
Company Overview
燃石医学 Burning Rock Biotech
燃石医学 Burning Rock Biotech

Current Openings: 0

About Burning Rock Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to guard life via science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of: 1) NGS-based therapy selection testing for late-stage cancer patients, with the leading market share in China and over 273,000 tissue and liquid-based tests completed cumulatively. 2) cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage. In July 2018, Burning Rock received the first approval for a tumor NGS kit by the National Medical Products Administration (NMPA), which is a significant milestone in the field of in vitro diagnosis in China. Burning Rock’s laboratory has obtained the technical certification of “High-throughput sequencing laboratory” issued by Guangdong Center for Clinical Laboratory, and the CLIA and CAP laboratory quality system certification. The company continues to be committed to the development of innovative and reliable NGS testing products and promoting the development of precision medicine in oncology. 燃石医学(纳斯达克代码:BNR)成立于2014年,公司使命为“用科学守护生命之光”,专注于为肿瘤精准医疗提供具有临床价值的二代基因测序(NGS)。公司业务及研发方向主要覆盖: 1)基于NGS的肿瘤患病人群检测,累计检测样本超过27万例,在中国拥有领先的市场份额; 2)基于NGS的癌症早检,目前已经进入临床验证阶段。 燃石医学于2018年7月获国家药品监督管理局(NMPA)颁发的中国肿瘤NGS检测试剂盒第一证,在体外诊断领域具有里程碑式意义。位于中国广州的实验室通过广东省临检中心颁发的“高通量测序实验室”技术审核,获得美国CLIA和CAP实验室质量体系资质认证;位于美国加利福尼亚州的实验室也已获得CLIA和CAP实验室质量体系资质认证。公司将继续致力于开发创新可靠的NGS检测产品,推动肿瘤精准医疗领域的发展。
Are you an employee? 🌟
Explore Biotech Jobs

Find the one that suits your cosmic aspirations. Search open positions across the web, find opportunities uniquely matched to your skills, and read reviews on companies worldwide. 🚀💼🌎

Are you an employer? 🌟

Hire Top Talent in the Biotechnology Industry.

Post jobs, search for stellar candidates, and conduct the complete hiring process—all from your desktop or mobile phone. 🚀🔬👩‍🚀